49 results about "Etiracetam" patented technology

The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-sero-tonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamaza-pine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.

The invention relates to a levetiracetam injection and a preparation method thereof. Specifically, the levetiracetam injection disclosed by the invention comprises the following components: levetiracetam, sodium chloride, sodium acetate buffer salt and injection water used as an injection solvent. The invention further relates to a method for preparing the levetiracetam injection. According to the invention, the levetiracetam injection disclosed by the invention is unexpectedly found to have good pharmaceutical properties.

The invention relates to a stable levetiracetam injection. In particular, the levetiracetam injection provided by the invention comprises levetiracetam, an acidic material, an alkaline material and injection water serving as an injection solvent. The pH value of the levetiracetam injection provided by the invention is 4.5-6.5. The invention further relates to a method for preparing the levetiracetam injection. The fact that the levetiracetam injection provided by the invention has good pharmaceutical properties is unexpectedly found.

The invention belongs to the technical field of medicament and provides a Levetiracetam osmotic pump controlled-release tablet and a preparation method thereof. The invention consists of the accessory of the Levetiracetam playing the effect of release control and a semi-transparent membrane; in the invention, proper accessory and medicament are mixed to press a tablet core at first; then a layer of semi-transparent membrane is coated outside the tablet core; then at least one small hole is punched on the semi-transparent membrane so as to lead active matters to be released from the semi-transparent membrane, thereby controlling the release of the medicament. Compared with a common preparation, the controlled-release preparation prepared by the invention has the advantages of small wave range of the blood medicine concentration, reducing toxic and side effect, being taken once in one day and improving the compliance of sufferers. The controlled-release preparation is applied on the adjunctive therapy for the partial seizure of epileptics in clinic.

The invention discloses a levetiracetam injection with a weight percent ratio of levetiracetam to cysteine of 10%:5%-10%; other auxiliary materials are sodium acetate, acetic acid, sodium chloride and injection water; the pH value of the injection is 5.0-6.5. The injection solves the problem that a process impurity of levetiracetam acid is increased slowly and the dosage is reduced during long-term storage of levetiracetam injections.

The invention discloses Sphingobacterium (sp.) SIT102 with the preservation number of CGMCC NO.6158 and a method for performing enantioselective hydrolysis to generate levetiracetam acid by utilizing the Sphingobacterium SIT102 serving as biocatalyst to catalyze racemization etiracetam acid esters. The method for preparing the levetiracetam acid comprises the steps of placing Sphingobacterium SIT102 cells into buffered solution, adding the racemization etiracetam acid esters into the buffered solution, performing the enantioselective hydrolysis through catalysis to obtain the levetiracetam acid. According to the method for preparing the levetiracetam acid by utilizing the Sphingobacterium SIT102 serving as the biocatalyst, the used biocatalyst is easy to prepare, the reaction condition is moderate, the yield of the levetiracetam acid can reach 48%, the enantiomer excess reaches 96%, and the production cost is low. Therefore, the method for preparing the levetiracetam acid by utilizing the Sphingobacterium has considerable industrial application development prospects.

The present invention discloses a levetiracetam preparation method, wherein (s)-2-aminobutanamide and 1,4-butyrolactone are adopted as starting raw material, and two reactions such as aminolysis ring opening and acid-catalyzed dehydration cyclization are performed to prepare the levetiracetam. According to the present invention, the method has characteristics of low price of the used starting materials, environmental protection, high product yield, high product optical purity, simple reaction process, and no requirement of repeated chiral resolution; and the levetiracetam preparation method provides the new selection for the preparation and the production of the drug levetiracetam.

The invention provides levetiracetam sustained release pellets. The levetiracetam sustained release pellets comprise medicine-containing pellets and coating layers, wherein the medicine-containing pellets are coated by the coating layers; the medicine-containing pellets comprise 250mg of levetiracetam, 70mg of hollow pellet cores, 60-110mg of filling agent, 18-68mg of lubricating agent and 2-10mg of adhesive; the coating layers comprise 45-225mg of Eudragit NE30D and 7-68mg of talcum powder. A preparation method of the levetiracetam sustained release pellets comprises the following processes: 1. material preparation; 2. mixing; 3. preparation of the adhesive; 4. preparation of the pellets; 5. preparation of a coating agent; 6. coating; 7. filling; 8. aluminium-plastic packaging and preparation of finished products. The levetiracetam sustained release pellets used for treating epilepsy and the preparation method have the beneficial effects that as the two kinds of advanced technologies, namely novel sustained release preparations and pellet preparations, are adopted, the levetiracetam sustained release pellets have stable treatment effects and higher bioavailability and have the advantages of good medicine stability, convenience in packaging, transportation and storage, and the like; the preparation method is simple and practicable and is suitable for industrial production.

The invention provides a levetiracetam sustained release tablet and a preparation method thereof. The preparation method provided by the invention is as below: drying raw materials and accessories for sustained release tablets; respectively weighing particles dividing into a blank layer (taking a release material and a binder according to the proportion of the blank layer, mixing uniformly according to an equal incremental method and sieving) and a sustained release layer (taking blending ratio of levetiracetam, a sustained-release material and a binder, according to the proportion of the release layer, mixing uniformly according to an equal incremental method and sieving); adding a lubricant; mixing uniformly; and pressing the mixture in two hopper of a bilayer tablet machine to obtain the tablets.

The invention discloses levetiracetam sustained-release tablets and a preparation method thereof, relates to the technical field of pharmaceutical preparations, and solves the problems that due to a poor release rate of levetiracetam sustained-release tablets, the actual pharmacological effect is greatly reduced, and the application effect is greatly reduced. The levetiracetam sustained-release tablets include the following components in percentages by weight: 45%-85% of levetiracetam, 1%-5% of a binder, 10%-50% of a sustained-release material, 0-2% of a flow aid, 0-2% of an anti-sticking agent, and 0-0.1% of a lubricant. The levetiracetam sustained-release tablets provided by the invention are easy to form as a whole, and have excellent release behavior and stable overall quality.

The invention discloses a preparation method of (S)-(+)-2-aminobutanamide hydrochloride, and relates to a preparation method of a levetiracetam key intermediate, and the method comprises the followingspecific steps: carrying out esterification reaction on L-2-aminobutyric acid serving as a starting material and thionyl chloride, and concentrating part of solvent after the reaction is finished; introducing ammonia gas to neutralize generated hydrogen chloride and residual thionyl chloride; and filtering, introducing ammonia gas, and carrying out an ammonolysis reaction to obtain the (S)-2-aminobutanamide hydrochloride after the treating is finished. According to the preparation method, the starting material is simple and easy to obtain, the one-pot method is adopted, the atom utilization rate is high, operation is easy and convenient, and the obtained product quality is high.

The invention relates to a pharmaceutical composition of levetiracetam and a preparation method thereof. The pharmaceutical composition comprises the following components in parts by weight: 0.3-6 parts of a disintegrating agent, 0.3-3 parts of an adhesive, 0.5-4 parts of a flow aid, 0.1-0.6 part of a lubricant and 92.6 parts of levetiracetam. The pharmaceutical composition of levetiracetam prepared by the invention has high stability; compared with the existing wet granulation and dry granulation, the disclosed preparation method has the characteristics of simple process, short operation time, low labor intensity and the like; and the prepared intermediate particles have good fluidity, and the pressed tablets are stable.

The invention relates to a preparation method of alpha-ethyl-2-oxo-1-pyrrolidine acetate. Particularly, by optimizing a post-treatment process, the reaction yield and the product purity are remarkably improved.

The invention belongs to the technical field of medicines, and particularly discloses a levetiracetam oral solution and a preparation method thereof. Each 150 ml of the levetiracetam oral solution comprises 12 to 20 g of levetiracetam, 0.1 to 0.2 g of a buffer agent, 0.3 to 0.5 g of a bacteriostatic agent, 45 to 50 g of a sweetening agent, 0.1 to 0.5 ml of an aromatic and the balance of a solvent.The preparation method comprises the following steps: dissolving the buffer agent in the solvent, heating the solvent to 70-80 DEG C, sequentially adding the bacteriostatic agent and the sweetening agent, performing uniform stirring, and keeping the temperature; cooling obtained mixture to 30-40 DEG C, adding the levetiracetam, performing stirring for dissolving, cooling stirred material to roomtemperature, adding the aromatic, performing uniform stirring, fixing the volume to full dose, performing uniform stirring, and performing filtration. The levetiracetam oral solution is proper in bacteriostatic agent content, good in bacteriostatic effect and high in safety; and in the preparation process, the increase of related substances of raw material medicines can be avoided through temperature rise and temperature reduction control.

The invention belongs to the technical field of medicine, and discloses levetiracetam composition, a preparation method and an application. The levetiracetam composition contains levetiracetam, sodiumacetate trihydrate, sodium chloride, glacial acetic acid and water for injection, and the average osmotic pressure molar concentration of the composition is 291-304 mOsmol/kg. The mass part ratio ofthe levetiracetam to the sodium acetate trihydrate to the sodium chloride is (250-500): (1.5-4): (0.5-12). The pH value of the composition is 5.5 +/-0.3. Aiming at the defects that a levetiracetam preparation in the prior art cannot be directly subjected to intravenous injection and the compliance of a patient is poor, the invention provides the isotonic levetiracetam injection preparation which meets the osmotic pressure requirement of intravenous injection and can be directly subjected to intravenous injection without compatibility.

The invention discloses a green production method of a levetiracetam key intermediate S-2-methyl aminobutyrate, and belongs to the field of medicine preparation, the method comprises the following steps: S1, pumping a mixture of S-2-aminobutyric acid, methanol and thionyl chloride into a reaction kettle, heating and stirring for reaction, and extracting the hydrogen chloride and the sulfur dioxidegenerated by reaction from the top of the reaction kettle; s2, pumping the hydrogen chloride and the sulfur dioxide extracted from the top of the reaction kettle into the bottom of an absorption tower, and pumping an alkaline aqueous solution into the tower top to absorb the hydrogen chloride and sulfur dioxide gas; and S3, discharging the reaction liquid from the bottom of the reaction kettle, and carrying out atmospheric distillation to obtain the S-2-methyl aminobutyrate. According to the process method provided by the invention, the hydrogen chloride and the sulfur dioxide generated in the production process of the S-2- methyl aminobutyrate are effectively absorbed, so that the process is greener and more environment-friendly, and meanwhile, the conversion rate of the S-2-methyl aminobutyrate in the obtained reaction product is greater than 88%.